Scarica l'app Stockscreener
182.64
22.75%
33.85
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché AXSM Giù?
Forum
Previsione
Precedente Chiudi:
$148.79
Aprire:
$158.49
Volume 24 ore:
3.04M
Relative Volume:
5.63
Capitalizzazione di mercato:
$9.21B
Reddito:
$338.46M
Utile/perdita netta:
$-310.96M
Rapporto P/E:
-27.97
EPS:
-6.53
Flusso di cassa netto:
$-132.82M
1 W Prestazione:
+18.88%
1M Prestazione:
+20.55%
6M Prestazione:
+74.96%
1 anno Prestazione:
+115.86%
Intervallo 1D:
$158.49
$184.40
Intervallo di 1 settimana:
$148.13
$184.40
Portata 52W:
$79.19
$184.40
Axsome Therapeutics Inc Stock (AXSM) Company Profile
Nome
Axsome Therapeutics Inc
Settore
Industria
Telefono
(212) 332-3241
Indirizzo
ONE WORLD TRADE CENTER, 29TH FLOOR, NEW YORK
Confronta AXSM con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
AXSM
Axsome Therapeutics Inc
|
182.64 | 7.50B | 338.46M | -310.96M | -132.82M | -6.53 |
|
VRTX
Vertex Pharmaceuticals Inc
|
453.36 | 115.12B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
771.87 | 81.34B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.65 | 52.48B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
840.95 | 51.59B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
174.04 | 37.13B | 447.02M | -1.18B | -906.14M | -6.1812 |
Axsome Therapeutics Inc Stock (AXSM) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-10-01 | Iniziato | B. Riley Securities | Buy |
| 2025-09-03 | Ripresa | Wells Fargo | Overweight |
| 2025-07-03 | Ripresa | Morgan Stanley | Overweight |
| 2025-06-03 | Iniziato | Oppenheimer | Outperform |
| 2025-04-07 | Iniziato | Jefferies | Buy |
| 2025-02-11 | Iniziato | Deutsche Bank | Buy |
| 2024-12-31 | Reiterato | Mizuho | Outperform |
| 2024-09-03 | Iniziato | Wells Fargo | Overweight |
| 2024-08-06 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2024-07-22 | Iniziato | Needham | Buy |
| 2024-04-29 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2024-03-19 | Iniziato | Robert W. Baird | Outperform |
| 2024-02-06 | Iniziato | UBS | Buy |
| 2024-01-25 | Iniziato | RBC Capital Mkts | Outperform |
| 2023-12-13 | Iniziato | Citigroup | Buy |
| 2023-08-08 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2023-01-05 | Iniziato | Piper Sandler | Neutral |
| 2022-11-01 | Iniziato | Loop Capital | Buy |
| 2022-09-07 | Ripresa | Mizuho | Buy |
| 2021-08-10 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2021-06-10 | Iniziato | Berenberg | Buy |
| 2021-01-08 | Iniziato | Jefferies | Buy |
| 2020-12-16 | Iniziato | Mizuho | Buy |
| 2020-09-29 | Iniziato | BofA Securities | Underperform |
| 2020-09-10 | Iniziato | Morgan Stanley | Overweight |
| 2020-04-28 | Reiterato | H.C. Wainwright | Buy |
| 2020-04-14 | Iniziato | Cowen | Outperform |
| 2019-12-30 | Reiterato | H.C. Wainwright | Buy |
| 2019-12-17 | Reiterato | H.C. Wainwright | Buy |
| 2019-12-16 | Reiterato | Guggenheim | Buy |
| 2019-10-16 | Iniziato | Guggenheim | Buy |
| 2019-09-18 | Iniziato | William Blair | Outperform |
| 2019-05-28 | Iniziato | SunTrust | Buy |
| 2019-05-23 | Reiterato | H.C. Wainwright | Buy |
| 2019-04-08 | Iniziato | SVB Leerink | Outperform |
| 2019-03-15 | Reiterato | H.C. Wainwright | Buy |
| 2016-10-03 | Ripresa | Brean Capital | Buy |
| 2015-12-15 | Iniziato | Cantor Fitzgerald | Buy |
| 2015-12-14 | Iniziato | Ladenburg Thalmann | Buy |
Mostra tutto
Axsome Therapeutics Inc Borsa (AXSM) Ultime notizie
Axsome (AXSM) Stock; Climbs Nearly 23% After FDA Accelerates Alzheimer’s Review - CoinCentral
Moody Aldrich Partners LLC Trims Stock Holdings in Axsome Therapeutics, Inc. $AXSM - MarketBeat
Axsome (AXSM) stock jumps after FDA sets April decision date for Alzheimer’s agitation filing - ts2.tech
Axsome stock jumps 23% after FDA sets April 30 deadline for Alzheimer’s agitation review - ts2.tech
Why Axsome Therapeutics Stock Rocketed Higher to End 2025 - The Globe and Mail
Axsome Therapeutics Stock Skyrockets: What’s Next? - StocksToTrade
Axsome stock jumps nearly 23% after FDA fast-tracks AXS-05 for Alzheimer’s agitation - ts2.tech
This Pharmaceutical Giant Fell by 10% After a Setback: Time to Sell the Stock? - AOL.com
Key Takeaways - StocksToTrade
Axsome’s Surprising Surge: What’s Next ? - timothysykes.com
From Haiti to Wall Street to Big Pharma: Herriot Tabuteau is on a $6B mission to heal the brain - AOL.com
Axsome Therapeutics price target raised to $217 from $202 at Mizuho - TipRanks
Baird reiterates Outperform rating on Axsome Therapeutics stock By Investing.com - Investing.com Nigeria
Axsome Therapeutics (AXSM) stock jumps 23% after FDA priority review for Alzheimer’s agitation filing - ts2.tech
Axsome Therapeutics says AXS-12 NDA submission on track for January - TipRanks
Baird reiterates Outperform rating on Axsome Therapeutics stock - Investing.com
Axsome Therapeutics Stock Surge Analysis - timothysykes.com
Axsome Therapeutics: Late-Stage CNS Pipeline and Regulatory Tailwinds Support Buy Rating - TipRanks
Mizuho raises Axsome Therapeutics stock price target on regulatory progress - Investing.com
Axsome stock jumps on FDA priority review for Alzheimer’s agitation drug - Investing.com
Mizuho raises Axsome Therapeutics stock price target on regulatory progress By Investing.com - Investing.com UK
Pharmaceutical Stocks To Follow NowDecember 31st - MarketBeat
Mizuho Lifts Price Target on Axsome Therapeutics to $217 From $202, Keeps Outperform Rating - marketscreener.com
Oppenheimer raises Axsome Therapeutics stock price target to $220 on FDA news - Investing.com
William Blair Maintains Axsome Therapeutics(AXSM.US) With Buy Rating - 富途牛牛
Axsome Therapeutics announces FDA acceptance, priority review of AXS-05 sNDA - TipRanks
Morgan Stanley reiterates Overweight rating on Axsome stock with $196 target - Investing.com
Axsome Therapeutics Stock Jumps After FDA Grants Priority Review For Alzheimer's Agitation Drug - Investor's Business Daily
Axsome’s Auvelity for Alzheimer’s agitation gets priority review - BioWorld MedTech
Axsome Advances Toward FDA Filing For Drug To Treat Narcolepsy - Stocktwits
Axsome Therapeutics Poised for Growth as AXS-05 Nears FDA Approval - timothysykes.com
Pharma Stock Soars to Record Highs on FDA Buzz - Schaeffer's Investment Research
Axsome nabs speedy review of Alzheimer's agitation drug hopeful - FirstWord Pharma
Why Is Axsome Therapeutics Stock Soaring Wednesday?Axsome Therapeutics (NASDAQ:AXSM) - Benzinga
Axsome Therapeutics (NASDAQ:AXSM) Hits New 52-Week High on Analyst Upgrade - MarketBeat
Axsome Therapeutics, Plug Power And Other Big Stocks Moving Higher On Wednesday - Benzinga
Biggest stock movers Wednesday: Vanda Pharmaceuticals, Axsome Therapeutics and Cybin - Seeking Alpha
Axsome Therapeutics stock hits all-time high at 160.6 USD By Investing.com - Investing.com Nigeria
Axsome Therapeutics stock hits all-time high at 160.6 USD - Investing.com
Axsome Therapeutics shares gain 8.3% after FDA grants priority review for co's Alzheimer's agitation drug - marketscreener.com
Axsome Therapeutics stock holds Buy rating at Truist on AXS-05 sNDA acceptance - Investing.com
Axsome Therapeutics (NASDAQ:AXSM) Has Debt But No Earnings; Should You Worry? - 富途牛牛
Axsome stock gets Buy rating from TD Cowen on FDA priority review - Investing.com
Needham & Company LLC Forecasts Strong Price Appreciation for Axsome Therapeutics (NASDAQ:AXSM) Stock - MarketBeat
Axsome stock surges after FDA grants priority review for Alzheimer’s drug - Investing.com
Why Axsome Therapeutics Shares Are Slipping Now - TipRanks
Axsome Therapeutics Says US FDA Accepts New-Drug Application Filing for Alzheimer's Disease Agitation Drug - marketscreener.com
Axsome Therapeutics to File AXS-12 New Drug Application in Narcolepsy After FDA Feedback - marketscreener.com
Axsome Advances AXS-12 Toward NDA Filing for Narcolepsy - TipRanks
Axsome wins FDA priority review for Auvelity in Alzheimer’s disease agitation - Seeking Alpha
Axsome Therapeutics shares gain 1.4% premarket after FDA grants priority review for co's Alzheimer's agitation drug - marketscreener.com
Axsome Therapeutics Inc Azioni (AXSM) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Axsome Therapeutics Inc Azioni (AXSM) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| TABUTEAU HERRIOT | Chief Executive Officer |
Dec 02 '25 |
Option Exercise |
8.02 |
49,252 |
395,001 |
56,481 |
| TABUTEAU HERRIOT | Chief Executive Officer |
Dec 03 '25 |
Option Exercise |
8.02 |
20,163 |
161,707 |
27,392 |
| TABUTEAU HERRIOT | Chief Executive Officer |
Dec 04 '25 |
Option Exercise |
8.02 |
10,558 |
84,675 |
17,787 |
| TABUTEAU HERRIOT | Chief Executive Officer |
Dec 02 '25 |
Sale |
144.59 |
49,252 |
7,121,347 |
7,229 |
| TABUTEAU HERRIOT | Chief Executive Officer |
Dec 03 '25 |
Sale |
146.94 |
20,163 |
2,962,751 |
7,229 |
| TABUTEAU HERRIOT | Chief Executive Officer |
Dec 04 '25 |
Sale |
148.18 |
10,558 |
1,564,484 |
7,229 |
0.90%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):